For the quarter ended June 2025, NovoCure (NVCR) reported revenue of $158.81 million, up 5.6% over the same period last year. EPS came in at -$0.36, compared to -$0.31 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $153.83 million, representing a surprise of +3.24%. The company delivered an EPS surprise of +7.69%, with the consensus EPS estimate being -$0.39.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how NovoCure performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenues- Greater China: $4.59 million compared to the $3.7 million average estimate based on two analysts.
- Geographic Revenues- Japan: $9.48 million compared to the $8.54 million average estimate based on two analysts.
- Geographic Revenues- United States: $94.26 million compared to the $93.78 million average estimate based on two analysts.
View all Key Company Metrics for NovoCure here>>>
Shares of NovoCure have returned -4.7% over the past month versus the Zacks S&P 500 composite's +5.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
NovoCure Limited (NVCR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
